PMID- 26303997
OWN - NLM
STAT- MEDLINE
DCOM- 20161213
LR  - 20221207
IS  - 1742-1241 (Electronic)
IS  - 1368-5031 (Print)
IS  - 1368-5031 (Linking)
VI  - 69
IP  - 12
DP  - 2015 Dec
TI  - Empagliflozin/linagliptin single-tablet combination: first-in-class treatment 
      option.
PG  - 1427-37
LID - 10.1111/ijcp.12720 [doi]
AB  - BACKGROUND: The availability of a dual sodium glucose co-transporter 2/dipeptidyl 
      peptidase-4 inhibitor combination in a single-tablet combination (STC) represents 
      a new therapeutic option for patients with type 2 diabetes. 
      Empagliflozin/linagliptin STC has been recently approved by the US Food and Drug 
      Administration for the treatment of type 2 diabetes mellitus (T2DM). AIM: The aim 
      of this study was to describe the latest clinical evidence on the efficacy and 
      safety profiles of empagliflozin/linagliptin STCs in comparison with the 
      individual components. Juxtaposition of the STC with dapagliflozin/saxagliptin 
      combination was also presented. RESULTS: Empagliflozin/linagliptin STC given as 
      initial therapy or on metformin background lowered mean glycated haemoglobin 
      (HbA1c) by approximately 1.1% (mean baseline HbA1c, 8.0%). Furthermore, the STC 
      reduced mean body weight by 2.0-3.0 kg from baseline. With the STC treatment, no 
      confirmed incidents of hypoglycaemia were reported in drug-naive patients; in 
      patients taking metformin hypoglycaemia occurred at low rates which were 
      comparable with monotherapy. Use of STCs in the treatment of T2DM can simplify 
      drug dosing regimen, reduce pill burden and increase treatment adherence. 
      Empagliflozin/linagliptin STC is a combination that offers potential additional 
      benefits such as body weight loss and moderate reductions in blood pressure, 
      without increasing risk of hypoglycaemia. CONCLUSION: Empagliflozin/linagliptin 
      STC appears to be a rational choice for a wide range of patients in need of 
      multiple agents for controlling hyperglycaemia. The STC should be particularly 
      useful in patients in whom hypoglycaemia, weight gain and treatment adherence are 
      of concern.
CI  - (c) 2015 The Authors. International Journal of Clinical Practice Published by John 
      Wiley & Sons Ltd.
FAU - Woo, V
AU  - Woo V
AD  - Section of Endocrinology and Metabolism, University of Manitoba, Winnipeg, MB, 
      Canada.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20150825
PL  - India
TA  - Int J Clin Pract
JT  - International journal of clinical practice
JID - 9712381
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Drug Combinations)
RN  - 0 (Glucosides)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 3X29ZEJ4R2 (Linagliptin)
RN  - HDC1R2M35U (empagliflozin)
SB  - IM
MH  - Benzhydryl Compounds/*administration & dosage/adverse effects
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Dipeptidyl-Peptidase IV Inhibitors/*administration & dosage/adverse effects
MH  - Drug Combinations
MH  - Glucosides/*administration & dosage/adverse effects
MH  - Glycated Hemoglobin/analysis
MH  - Humans
MH  - Hyperglycemia/drug therapy
MH  - Hypoglycemic Agents/*administration & dosage/adverse effects
MH  - Linagliptin/*administration & dosage
MH  - Randomized Controlled Trials as Topic
PMC - PMC5049636
EDAT- 2015/08/26 06:00
MHDA- 2016/12/15 06:00
PMCR- 2016/10/04
CRDT- 2015/08/26 06:00
PHST- 2015/08/26 06:00 [entrez]
PHST- 2015/08/26 06:00 [pubmed]
PHST- 2016/12/15 06:00 [medline]
PHST- 2016/10/04 00:00 [pmc-release]
AID - IJCP12720 [pii]
AID - 10.1111/ijcp.12720 [doi]
PST - ppublish
SO  - Int J Clin Pract. 2015 Dec;69(12):1427-37. doi: 10.1111/ijcp.12720. Epub 2015 Aug 
      25.